The acquisition is expected to offer limited competition products to its US retail prescription pharma business.
Based on the decision of the 109th authority meeting held on February 21 this year, the NPPA has fixed the prices.
Grant has been given by Central Government.
The facility is expected to generate employment for 1500 people.
Biologicals, Biosimilars etc. are manufactured in Telangana plant.
Annual market for these tablets in US is $4.2 billion, currently.
Total purchase price of the two deals is Rs 179 crore.
The company has said that it will address the issues raised by USFDA.
The EIR was issued following the facility's most recent inspection in October.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
